New Delhi (PTI): UK-based pharmaceutical major AstraZeneca has started global withdrawal of its COVID-19 vaccine, which was provided in India as 'Covishield' in partnership with Serum Institute of India, days after it admitted to rare side effects of blood clotting and low platelet counts.

The withdrawal has been initiated due to a surplus of available updated vaccines since the pandemic, the company said in a statement.

AstraZeneca had partnered with Oxford University to develop the COVID-19 vaccine, which was sold in India as Covishield and as Vaxzevria in Europe.

"As multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines. This has led to a decline in demand for Vaxzervria, which is no longer being manufactured or supplied," it said.

The company further said, "We will now work with regulators and our partners to align on a clear path forward to conclude this chapter and significant contribution to the COVID-19 pandemic."

Earlier, according to global media reports, AstraZeneca had admitted that its COVID-19 vaccine could in very rare cases has the potential to cause a rare side effect called -- Thrombosis with Thrombocytopenia Syndrome (TTS).

Without referring to the side effects, the company said, "we are incredibly proud of the role Vaxzevria played in ending the global pandemic. According to independent estimates, over 6.5 million lives were saved in the first year of use alone and over three billion doses were supplied globally."

It further said, "our efforts have been recognised by governments around the world and are widely regarded as being a critical component of ending the global pandemic."

In India, over 220 crore dosages of COVID-19 vaccines have been administered and a majority of those were Covishield.

 

Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.



New Delhi (PTI): The government has promulgated an ordinance to increase the strength of the Supreme Court from the present 34 judges to 38, including the Chief Justice of India.

The law ministry notified the ordinance on Saturday, which amended the Supreme Court (Number of Judges) Act, 1956, to increase the sanctioned strength of the top court.

So far, the sanctioned strength of the top court was 34, including the Chief Justice of India (CJI). Now, the number of judges has been increased by four, taking the sanctioned strength to 38.

The top court will now have 37 judges, other than the CJI.

With the apex court having two vacancies at present, and the ordinance coming into force immediately, the Supreme Court Collegium will now have to recommend six names for appointment as judges in the top court.

A bill will be brought in the Monsoon Session of Parliament to convert the ordinance – an executive order – into a law passed by Parliament.

The Union Cabinet had cleared a draft bill on May 5 to increase the number of apex court judges.

The strength of the Supreme Court was last increased from 30 to 33 (excluding the CJI) in 2019.

The Supreme Court (Number of Judges) Act, as originally enacted in 1956, put the maximum number of judges (excluding the CJI) at 10.

This number was increased to 13 by the Supreme Court (Number of Judges), Amendment Act, 1960, and to 17 by another amendment to the law.

The Supreme Court (Number of Judges) Amendment Act, 1986, augmented the strength of judges from 17 to 25, excluding the CJI.

A fresh amendment in 2009 further increased the strength from 25 to 30.

Article 124(3) of the Constitution lists the qualifications required to become a Supreme Court judge.

An Indian citizen who has either served as a high court judge for at least five years, or as an advocate for 10 years, or is a distinguished jurist, can be appointed to the top court.

The strength of the Supreme Court is increased based on the recommendations of the CJI, who writes to the Union law minister. After consulting the finance ministry, the Department of Justice under the law ministry moves the Cabinet with a draft bill.